



(Original Signature of Member)

117TH CONGRESS
1ST SESSION

H. R. _____

To amend the Public Health Service Act to authorize grants for acquiring equipment and supplies capable of performing same-day clinical laboratory testing in a point-of-care setting, and to assist laboratories in meeting the cost of acquiring high-throughput equipment, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Ms. DEGETTE introduced the following bill; which was referred to the
Committee on _____

A BILL

To amend the Public Health Service Act to authorize grants for acquiring equipment and supplies capable of performing same-day clinical laboratory testing in a point-of-care setting, and to assist laboratories in meeting the cost of acquiring high-throughput equipment, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Access to Technology
3 and Equipment for Same-day Tests Act” or the “Access
4 to TESTs Act”.

5 **SEC. 2. GRANTS FOR SAME-DAY POINT-OF-CARE TESTING**
6 **IN COMMUNITIES.**

7 Section 2821 of the Public Health Service Act (42
8 U.S.C. 300hh–31) is amended—

9 (1) by redesignating subsection (b) as sub-
10 section (d); and

11 (2) after making such redesignation, by insert-
12 ing after subsection (a) the following new subsection:

13 “(b) GRANTS FOR SAME-DAY POINT-OF-CARE TEST-
14 ING IN COMMUNITIES.—

15 “(1) GRANTS.—The Secretary, acting through
16 the Director of the Centers for Disease Control and
17 Prevention, shall award grants to eligible entities to
18 assist such entities in acquiring legally-marketed
19 equipment and supplies capable of performing, stor-
20 ing, and processing same-day clinical laboratory test-
21 ing, including molecular, serological, and antigen
22 tests, in a point-of-care setting.

23 “(2) ELIGIBILITY.—To be eligible for a grant
24 under paragraph (1), an entity shall—

25 “(A) be—

26 “(i) a hospital;

1 “(ii) a primary care facility;

2 “(iii) a clinic;

3 “(iv) a pharmacy;

4 “(v) a physician; or

5 “(vi) such other type of health care

6 provider as the Secretary may determine

7 for purposes of this section;

8 “(B) be in compliance with section 353

9 (commonly referred to as the ‘Clinical Labora-

10 tory Improvement Amendments of 1988’); and

11 “(C) submit to the Secretary an applica-

12 tion at such time, in such manner, and con-

13 taining such information as the Secretary may

14 reasonably require.

15 “(3) AMOUNT OF GRANT.—The amount of a

16 grant under paragraph (1) may not exceed \$20,000.

17 “(4) PRIORITY.—In awarding grants under

18 paragraph (1), the Secretary shall give highest pri-

19 ority to eligible entities providing services to—

20 “(A) underserved populations in rural

21 areas; and

22 “(B) medically underserved populations (as

23 defined in section 330(b)(3)).”.

1 **SEC. 3. GRANTS FOR LABORATORIES TO ACQUIRE HIGH-**
2 **THROUGHPUT DIAGNOSTIC EQUIPMENT.**

3 Section 2821 of the Public Health Service Act (42
4 U.S.C. 300hh–31) is amended by inserting after sub-
5 section (b) (as added by section 2) the following new sub-
6 section:

7 “(c) GRANTS FOR LABORATORIES TO ACQUIRE
8 HIGH-THROUGHPUT DIAGNOSTIC EQUIPMENT.—

9 “(1) GRANTS.—The Secretary, acting through
10 the Director of the Centers for Disease Control and
11 Prevention, shall award grants to eligible entities to
12 assist such entities in purchasing high-throughput
13 diagnostic equipment and related supplies to admin-
14 ister, store, and process molecular, serological, and
15 antigen tests.

16 “(2) ELIGIBILITY.—To be eligible for a grant
17 under paragraph (1), an entity shall—

18 “(A) be—

19 “(i) a State, local, or Tribal public
20 health laboratory;

21 “(ii) a laboratory within a public
22 health laboratory network coordinated or
23 managed by the Centers for Disease Con-
24 trol and Prevention;

25 “(iii) a laboratory not described in
26 clause (i) or (ii) that the Secretary deter-

1 mines (at the Secretary’s discretion) pro-
2 vides population-based testing for the pre-
3 vention and control of infectious, commu-
4 nicable, genetic, or chronic diseases; or

5 “(iv) a consortium of 2 or more enti-
6 ties described in any of clauses (i) through
7 (iii); and

8 “(B) submit to the Secretary an applica-
9 tion at such time, in such manner, and con-
10 taining such information as the Secretary may
11 reasonably require.

12 “(3) AMOUNT OF GRANT.—The amount of a
13 grant under paragraph (1) may not exceed
14 \$2,000,000, except in the case of eligible entity de-
15 scribed in paragraph (2)(A)(iv).

16 “(4) HIGH-THROUGHPUT DIAGNOSTIC EQUIP-
17 MENT DEFINED.—In this subsection, the term ‘high-
18 throughput diagnostic equipment’ means legally-
19 marketed equipment capable of performing multi-
20 channel analysis for use in clinical laboratory test-
21 ing, including molecular, serological, and antigen
22 tests.”.

1 **SEC. 4. AUTHORIZATION OF APPROPRIATIONS.**

2 Section 2821(d) of the Public Health Service Act (42
3 U.S.C. 300hh–31(d)) (as redesignated by section 2) is
4 amended to read as follows:

5 (1) by striking “There are authorized to be ap-
6 propriated to carry out this section” and inserting
7 the following:

8 “(1) IN GENERAL.—There is authorized to be
9 appropriated to carry out subsection (a)”; and

10 (2) by adding at the end, the following:

11 “(2) AUTHORIZATION OF APPROPRIATIONS.—

12 “(A) TESTING GRANTS.—For carrying out
13 subsection (b), there is authorized to be appro-
14 priated \$500,000,000 for fiscal year 2021, to
15 remain available until expended.

16 “(B) EQUIPMENT GRANTS.—For carrying
17 out subsection (c), there is authorized to be ap-
18 propriated \$250,000,000 for fiscal year 2021,
19 to remain available until expended.

20 “(C) ADMINISTRATIVE EXPENSES.—Of the
21 total amount made available to carry out sub-
22 sections (b) and (c) for any fiscal year, the Sec-
23 retary may not use more than 5 percent of such
24 amount for the expenses of administering such
25 subsections.”.